Impaired dopamine release in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease is the second most common neurodegenerative disease and yet the early pathophysiological events of the condition and sequences of dysfunction remain unclear. The loss of dopaminergic neurons and reduced levels of striatal dopamine are descriptions used interchangeably as underlying the motor deficits in Parkinson’s disease. However, decades of research suggest that dopamine release deficits in Parkinson’s disease do not occur only after cell death, but that there is dysfunction or dysregulation of axonal dopamine release before cell loss. Here we review the evidence for dopamine release deficits prior to neurodegeneration in Parkinson’s disease, drawn from a large and emerging range of Parkinson’s disease models, and the mechanisms by which these release deficits occur. The evidence indicates that impaired dopamine release can result from disruption to a diverse range of Parkinson’s disease-associated genetic and molecular disturbances, and can be considered as a potential pathophysiological hallmark of Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This lack of dopamine is understood to be the primary cause of many of the movement disorders [127,128].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469 · cited 1×
“1).(2,3) SNpc neurons project to the dorsal striatum form-”
BackgroundMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 2×
“Loss-of-function mutations in parkin are the most common cause of autosomal recessive Parkinson’s.95 Parkin, encoded by the PRKN gene (previously known as PARK2), is an E3 ubiquitin ligase that regulates proteasome-dependent protein degradation and plays a critical role in mitochondrial quality control.”
BackgroundAGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529 · cited 1×
“1).(2,3) SNpc neurons project to the dorsal striatum form-”
BackgroundHereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481 · cited 1×
“PINK1 is a mitochondrial protein kinase in which loss-of-function mutations are the second most frequent known cause of autosomal recessive Parkinson’s disease.(96) This protein regulates the activity of parkin, affects mitochondrial stability and modulates mito-”
BackgroundMutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563 · cited 1×
“Models employing SNpc or intrastriatal PFF injections that take advantage of the connectivity to the SNpc have the advantages that they have been shown to aggregate endogenous α-synuclein, induce progressive DA system neurodegeneration specific to SNpc while sparing the ventral tegmental area and recapitulate Parkinso…”
BackgroundThe Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro
Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M. R., & Südhof, T. C. (2010) · Science · doi:10.1126/science.1195227 · Cited by 1,812
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765 · cited 2×
“TH, the rate-limiting enzyme in DA synthesis, has been shown to have decreased protein levels or decreased activity in models of Parkinson’s disease carrying mutations in LRRK2, SNCA, DJ-1 and PINK1.”
BackgroundMice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Cited by
Items 201–228 of 228
Liang, T., Pang, X., Liu, Q., Sun, S., Wang, L., & Yan, H. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111111
Neurodegeneration in Parkinson’s Disease: The Role of Environmental Toxins
Rissardo, J. P., Katz, M., Byroju, V. V., Caprara, A. L. F., & Walker, I. M. (2026) · Journal of Central Nervous System Disease · doi:10.1177/11795735261461554
Liu, M., Xue, J., Cao, Y., Hao, Z., Wang, Y., Li, J., Jiang, T., Zhang, G., & Shi, J. (2026) · npj Biofilms and Microbiomes · doi:10.1038/s41522-026-01110-8
Benhaiba, S., Elgamouz, A., Kawde, A.-N. M., Ezzahi, A., & Rhazi, M. E. (2026) · ECS Sensors Plus · doi:10.1149/2754-2726/ae96be
Влияние дофаминергической системы на развитие болезни Паркинсона и шизофрении
Артюхович, Д. А., & Лаптева, Н. А. (2026) · Смоленский медицинский альманах · doi:10.37903/sma.2026.1.6
Adak, R., Kumar, P., Yadav, S. S., Chaudhary, S., & Datusalia, A. K. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.07.006
Zhou, C., Zhu, C., Wang, X., Yang, Y., & Wei, J. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179275
Multitargeted drug strategies for Alzheimer’s and Parkinson’s diseases
Khan, A. U., Abdullah, A., Naqvi, S. F., Tahir, H., Khalid, H., Sarfraz, H., & Khan, Y. (2026) · Zeitschrift für Naturforschung C · doi:10.1515/znc-2026-0116
“PD is caused mainly by the loss of brain cells that produce dopamine [25].”
Chu, S., Yang, L., Chi, Z., Ma, J., Wang, H., Yan, L., Li, Z., & Liu, G. (2026) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-026-06814-6
The 6-OHDA Model of Parkinson’s Disease: Mechanisms, Applications, and Limitations
Ma, Y. (2026) · Transactions on Materials Biotechnology and Life Sciences · doi:10.62051/2v1mqa20
“The relationship of DA depletion and deficits in motor functions was confirmed by understanding the PD pathologies and by conducting TH assessment via immunofluorescence and behavioural tests [8].”
Understanding Neuropsychiatric Fluctuations in Parkinson's Disease: From Mechanisms to Management
Sousa, M., Amstutz, D., Natera‐Villalba, E., Krack, P., & Martínez‐Fernández, R. (2026) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70771
Khan, A., Tahir, M., Anwar, M., Hassan, S. U., Rehman, A. U., Ahmad, I., Di, W., Kalhoro, K. A., & Liu, Z. (2026) · Electrochimica Acta · doi:10.1016/j.electacta.2026.150061
Markosyan, G. A., Tarutta, E. P., Papyan, V. N., Иомдина, Е. Н., Pavlenko, T. A., Валерьевна, Б. О., Larina, T. Y., & Kushnarevich, N. Y. (2026) · Russian Ophthalmological Journal · doi:10.21516/2072-0076-2026-19-3-42-48
Dopaminergic transmissive dormancy as a protective state against cellular stress
Zuurbier, K. R., Fonseca, R. S., Snowden, J., & Douglas, P. M. (2026) · Genes & Development · doi:10.1101/gad.353957.126
Dopaminergic treatments for Parkinson's disease: Seeing the unseen
Awan, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27702-3.00028-5
Case report: Dystonia and athetosis in ICH of 80 years old female patient
Kristiani, A., & Sunarnyo, S. (2024) · Science Midwifery
Nanoparticles targets for Alzheimer’s and Parkinson’s disease
Bharti, S. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.003
Rathnayake, U. A., Bungard, J. D., Maurer, M. A., Kethanapalli, S. H., Presley, C. C., Manore, S., Chang, S., Schley, N. D., Zagol-Ikapitte, I. A., Watson, K. J., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00482
Understanding lncRNA NL02 Deficiency in Parkinson's Disease
Wewalage, T. (2025) · Otago University Research Archive (University of Otago)
Liao, X., Yang, H., Lin, P., & Chen, S. (2026) · Materials Today Physics · doi:10.1016/j.mtphys.2026.102275
Li, J., Yang, X., Wang, J., Yu, C., Lu, J., Lian, W., Liu, W., & Zhao, Y. (2026) · Nutrients · doi:10.3390/nu18203412
“Reduced dopamine synthesis is a core cause of motor symptoms in PD [34].”
Zadrożny, M., Zadrożna, P., Niewiadomski, W., Riedel, G., Harrington, C. R., Wischik, C. M., Niewiadomska, G., & Gąsiorowska, A. (2026) · Cells · doi:10.3390/cells15201908
“…from Parkinson’s disease, in which substantial nigrostriatal dopaminergic degeneration can occur before the manifestation of motor symptoms, with estimates of approximately 50–70% neuronal loss in the substantia nigra and ~70–80% reductions in striatal dopamine levels at symptom onset [65,72,73].”
Early-life PFAS exposure induces systemic metabolic alterations in plasma and brain in micePreprint
Hyötyläinen, T., Duberg, D., Evstafev, I., Dickens, A. M., Savontaus, E., & Oresic, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.14.758497
Lee, K., Lee, M., Jiang, H., & Kim, H. F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.19.760032 · Cited by 1
Akande, R., Kustermann, T., Holiga, Š., Anzures‐Cabrera, J., Brundin, P., & Pagano, G. (2026) · Movement Disorders · doi:10.1002/mds.70588
Wang, H., Xu, H., Liu, H., An, S., Chen, Z., Zhang, A., Zhao, Q., Zhang, S., & Xu, G. (2026) · Brain Sciences · doi:10.3390/brainsci16111173
Pregnancy Outcomes Following Maternal Exposure to Pramipexole: A TERAFAR Case Series
Bakırlı, D. C., Horoz, E., Kuragi, C. C., Gungor, M., Karakulak, O., Temiz, T. K., Karadaş, B., Yilmaz, I. C., & Kaplan, Y. C. (2026) · Birth Defects Research · doi:10.1002/bdr2.70126
Riaz, A., Abedin, Z. U., Afroz, E., Yaseen, F., Akhtar, I., & Amin, J. H. J. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005114
Metadata
- Authors
- Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R.
- Affiliations
- University of Oxford (GB)
- Oxford Parkinson’s Disease Centre and Department of Physiology, Anatomy and Genetics, University of Oxford , Oxford, OX1 3QU , UK
- Corresponding author
- Cragg, Stephanie J
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-02
- Volume
- 146
- Issue
- 8
- Pages
- 3117-3132
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC10393405
- OpenAlex
- W4323036321
- Cited by
- 207
- References
- 157
- Citations by year
- 2026: 63 · 2025: 75 · 2024: 60 · 2023: 8
- FWCI
- 8.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Monument Trust Discovery Award from Parkinson’s UK (J-1403)
- MJFF (ASAP-020370)
- Natural Sciences and Engineering Research Council of Canada (PGSD3-517039-2018)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- Parkinson's disease, dopamine release, dopaminergic neurons, striatal dopamine, neurodegeneration, Parkinson's disease model, pathophysiology
- MeSH terms
- Dopamine, Humans, Parkinson Disease, Neurodegenerative Diseases, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.